Clene plans Phase 3 ALS trial in Q2 2027
Clene plans to initiate the Phase 3 RESTORE-ALS confirmatory trial of CNM-Au8 in the second quarter of 2027.
Clene plans to initiate the Phase 3 RESTORE-ALS confirmatory trial of CNM-Au8 in the second quarter of 2027.